Vaccine
Herpes-zoster vaccine (recombinant, adjuvanted)
Brand names: Shingrix
Adult dose
Dose: 2 doses 2–6 months apart (or 1–2 months apart in immunocompromised)
Route: IM
Frequency: 2-dose course
Clinical pearls
- UK shingles programme: now offered to immunocompromised ≥18 and adults ≥60–65y per current Green Book schedule
- Replaces Zostavax (live)
Contraindications
- Severe hypersensitivity to previous dose
Side effects
- Local reaction (common)
- Myalgia
- Fatigue
- Headache
Interactions
- Other vaccines may be co-administered
Reference: BNF; UK Green Book; JCVI advice; https://bnf.nice.org.uk/drugs/herpes-zoster-vaccine-recombinant-adjuvanted/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023